Immunological Reprogramming by Radiation Therapy: Implications for Precision Cancer Treatment

Area of Science:

• Radiation oncology
• Cancer immunology
• Tumor microenvironment modulation

Background:

• Radiation therapy (RT) primarily kills cancer cells but also modulates the immune system.
• Recent research highlights RT's role in reprogramming the tumor microenvironment (TME) and activating systemic anti-tumor immunity.

Purpose of the Study:

• To review immune mechanisms of tumor killing post-irradiation.
• To assess RT's synergy with immune checkpoint inhibitors (ICIs).
• To provide a framework for harnessing radiation-induced immune reprogramming in precision oncology.

Main Methods:

• Review of immunogenic cell death (ICD), cGAS-STING pathway, dendritic cell (DC) maturation, cytotoxic T lymphocyte (CTL) priming, and abscopal effect.
• Analysis of RT-induced immunosuppressive mechanisms (Tregs, MDSCs, PD-L1).
• Critical assessment of RT combined with ICIs (anti-PD-1, anti-PD-L1, anti-CTLA-4).
• Comparison of RT and chemotherapy (ChX) in inducing neo-antigens and immune activation.
• Focus on dose fractionation effects (SBRT, SRS) and tumor type susceptibility (e.g., melanoma).

Main Results:

• RT induces both anti-tumor immune responses and immunosuppressive counterforces.
• Synergy between RT and ICIs shows promise, but potential side effects require consideration.
• Dose fractionation, particularly SBRT and SRS, influences immunogenic effects.
• Malignant melanoma is highly susceptible to RT-induced immune responses.

Conclusions:

• Radiation therapy possesses significant immunomodulatory properties that can be leveraged for cancer treatment.
• Understanding RT's complex immune effects is crucial for designing next-generation precision oncology strategies.
• Further research into RT-ICI combinations and optimal fractionation is warranted.